Results 41 to 50 of about 13,617 (225)

Pharmacokinetic equivalence of CT‐P39 and reference omalizumab in healthy individuals: A randomised, double‐blind, parallel‐group, Phase 1 trial

Clinical and Translational Allergy, 2022
Background CT‐P39 is being developed as a biosimilar of reference omalizumab. This study aimed to assess the pharmacokinetic equivalence of CT‐P39 to European Union‐approved and United States‐licensed reference omalizumab (EU‐ and US‐omalizumab ...
Marcus Maurer, Sarbjit S. Saini, Kristi McLendon, Paul Wabnitz, Sunghyun Kim, Keumyoung Ahn, Suyoung Kim, Sewon Lee, Clive Grattan   +8 more
doaj   +1 more source

Effectiveness and pharmacoeconomic analysis of the treatment of severe asthma with omalizumab in clinical practice [PDF]

, 2019
Objetivo: Evaluar el gasto sociosanitario tras la incorporación de omalizumab al tratamiento estándar en el control del asma grave, así como analizar su efectividad, en condiciones de práctica clínica.
Sánchez-Toril, Fernando, Climent, María, Grupo de trabajo del estudio Impacto Farmacoeconómico del Uso de Omalizumab, Fernández-Aracil, Cleofé, Lluch-Tortajada, Inmaculada, Martínez-Moragón, Eva, Chiner, Eusebi   +6 more
core   +1 more source

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

Barrier Immunity, EarlyView.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu, Shih‐Yu Hung, Fatma Saaoud, Ying Shao, Yifan Lu, Juanjuan Liu, Bo Yuan, Haiyan Xiang, Hong Wang, Xiaofeng Yang   +9 more
wiley   +1 more source

Omalizumab rescue therapy in refractory status asthmaticus

, 2023
Introduction: Refractory status asthmaticus (RSA) is a severe, life-threatening form of asthma exacerbation that persists despite aggressive treatment with systemic corticosteroids, bronchodilators, and other supportive measures. Omalizumab, a monoclonal
Dey, Akash, Akash Dey, Srivatsa Lokeshwaran, Shashank M. R., Gayathri, Lakshmi, Sanjana Chetana Shanmukhappa, Lokeshwaran, Srivatsa, Kumar K, Sunil, M R, Shashank, Sunil Kumar K., Doraiswamy, Prakash, Arun Kumar, Prakash Doraiswamy, Lakshmi Gayathri, Chetana Shanmukhappa, Sanjana, Kumar, Arun, Janani J.V.S., J V S, Janani   +17 more
core   +1 more source

Inflammatory Factors in Allergic Rhinitis: A 20‐Year Bibliometric Mapping and Emerging Trends

Flavour and Fragrance Journal, EarlyView.
This figure illustrates the bibliometric process and results of research on inflammatory factors of allergic rhinitis from 2004 to 2024 including data screening, global distribution, collaborative networks and the evolution of research hotspots. ABSTRACT Allergic rhinitis (AR) is driven by a network of inflammatory mediators released by mast cells ...
Shanshan Jing, Fengying Zhang, Qiqi Liu
wiley   +1 more source

Appropriate selection for omalizumab treatment in patients with severe asthma?

European Clinical Respiratory Journal, 2017
Background: Omalizumab improves asthma control in patients with uncontrolled severe allergic asthma; however, appropriate patient selection is crucial. Information in this field is sparse.
Leo Nygaard, Daniel Pilsgaard Henriksen, Hanne Madsen, Jesper Rømhild Davidsen   +3 more
doaj   +1 more source

Profile of omalizumab in the treatment of chronic spontaneous urticaria

, 2015
Moises Labrador-Horrillo,1 Marta Ferrer2 1Allergy Section, Internal Medicine Department, Vall d’Hebron Hospital, Universitat Autònoma de Barcelona, Barcelona, 2Department of Allergy and Clinical Immunology, Clínica Universidad de ...
Labrador-Horrillo M, Moises Labrador-Horrillo, Ferrer M, Marta Ferrer   +3 more
core   +1 more source

Integrative Analysis of Plasma Proteome and Genome Reveals Novel Drug Targets for Chronic Rhinosinusitis and Nasal Polyps

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) and nasal polyps (NP) are chronic inflammatory conditions with unsatisfactory treatment outcomes due to frequent recurrence of refractory disease. Identifying new therapeutic targets is essential. Methods We conducted a proteome‐wide Mendelian randomization (MR) analysis by integrating genome‐wide ...
En Zhou, Shi Luo, Yu Xiao, Bin Liu, Xu‐Ping Xiao   +4 more
wiley   +1 more source

Cost-effectiveness of fractional exhaled nitric oxide (FeNO) measurement in predicting response to omalizumab in asthma

ClinicoEconomics and Outcomes Research, 2019
Elizabeth A Brooks,1 Marc Massanari,2 Nicola A Hanania,3 Daniel J Weiner11TTi Health Research & Economics, Health Research & Economics, Westminster, MD, USA; 2Circassia Pharmaceuticals, Global Medical Affairs, Morrisville, NC, USA; 3Section of ...
Brooks EA, Massanari M, Hanania NA, Weiner DJ   +3 more
doaj  

Case Report: Omalizumab-associated hair loss: a case of eyebrow alopecia areata, literature review and FAERS database analysis

Frontiers in Medicine
Hair loss is a rare adverse reaction associated with omalizumab, with limited literature reports. The incidence, underlying mechanisms, and clinical characteristics of omalizumab-associated hair loss have not been clarified.
Qian Wang, Hua Lei, Ge Yang, Ying Li, Wei Liu, Lixia Zhang, Xiyuan Zhou   +6 more
doaj   +1 more source